Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 agonist RG 7697 after single subcutaneous administration in healthy subjects

Jul 26, 2017Diabetes, obesity & metabolism

How the new dual hormone drug RG7697 is processed, works, and is tolerated after a single injection in healthy people

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

RG7697 was generally well tolerated in healthy participants after subcutaneous injections up to 3.6 mg.

Gastrointestinal side effects, such as nausea and vomiting, were noted at the highest dose.
A small dose-dependent increase in heart rate was observed.
No episodes of hypoglycemia occurred during the study.
RG7697 concentrations peaked 2 to 4 hours post-dose and had a half-life of 19 to 25 hours.
At doses of 1.8 mg or higher, RG7697 reduced glucose maximum plasma concentration by 46% and insulin levels by 64%.

AI simplified

AIMS: To evaluate the pharmacodynamics, pharmacokinetics and safety of single subcutaneous (s.c.) injection of ascending doses of RG7697, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist, in healthy subjects.

METHODS: A total of 51 healthy volunteers were enrolled in this double-blind, placebo-controlled study investigating RG7697 doses ranging from 0.03 to 5 mg. Adverse events (AEs) were monitored and drug concentrations, fasting glycaemic variables, vital signs, ECG, antibody formation and routine laboratory variables were assessed. A meal tolerance test (MTT) was performed at the same time on day -1 (baseline) and day 1.

RESULTS: RG7697 was generally well tolerated in healthy participants after s.c. injections up to 3.6 mg. Tolerability was limited by gastrointestinal AEs (nausea and vomiting) at the highest dose. There was a small dose-dependent increase in heart rate. No episodes of hypoglycaemia occurred. RG7697 concentrations peaked at 2 to 4 hours post-dose with a half-life of 19 to 25 hours. During MTT, RG7697 at doses ≥1.8 mg, reduced glucose maximum plasma concentration (C; -46%) without affecting overall glucose area under the curve (AUC). Its effect on insulin was more pronounced, with reductions in both C(-64%) and AUC (-51%). Pharmacodynamic variables were well correlated to RG7697 average plasma concentration during MTT, with IC(average concentration required for 50% reduction) values of 49 and 24.5 ng/mL for glucose and insulin, respectively. max max50

CONCLUSION: Single s.c. injections of RG7697 up to 3.6 mg were generally well tolerated. Evidence of glycaemic effect and pharmacokinetic profiles consistent with once-daily dosing render this drug candidate suitable to be further tested in multiple-dose clinical trials in patients with type 2 diabetes.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text ↗

Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 agonist RG 7697 after single subcutaneous administration in healthy subjects

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief